miércoles, 19 de agosto de 2015

Emerging Infections Program as Surveillance for Antimicrobial Drug Resistance - Volume 21, Number 9—September 2015 - Emerging Infectious Disease journal - CDC


Emerging Infections Program as Surveillance for Antimicrobial Drug Resistance - Volume 21, Number 9—September 2015 - Emerging Infectious Disease journal - CDC

Volume 21, Number 9—September 2015
Emerging Infections Program

Emerging Infections Program

Emerging Infections Program as Surveillance for Antimicrobial Drug Resistance

Scott K. FridkinComments to Author , Angela A. Cleveland, Isaac See, and Ruth Lynfield
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.K. Fridkin, A.A. Cleveland, I. See)Minnesota Department of Public Health, St. Paul, Minnesota, USA (R. Lynfield)


Across the United States, antimicrobial drug–resistant infections affect a diverse population, and effective interventions require concerted efforts across various public health and clinical programs. Since its onset in 1994, the Centers for Disease Control and Prevention Emerging Infections Program has provided robust and timely data on antimicrobial drug–resistant infections that have been used to inform public health action across a spectrum of partners with regard to many highly visible antimicrobial drug–resistance threats. These data span several activities within the Program, including respiratory bacterial infections, health care–associated infections, and some aspects of foodborne diseases. These data have contributed to estimates of national burden, identified populations at risk, and determined microbiological causes of infection and their outcomes, all of which have been used to inform national policy and guidelines to prevent antimicrobial drug–resistant infections.
The 1992 Institute of Medicine report Emerging Infections: Microbial Threats to Health in the United States describes the ability of microbes to adapt, the development of antimicrobial drug resistance, and the importance of recognizing and monitoring emerging microbial threats to human health (1). In response, because of the recognized need for more accurate surveillance to detect and address emerging microbial health threats, in 1994 the Centers for Disease Control and Prevention (CDC) Emerging Infections Program (EIP) was established as a collaboration of CDC and state health departments and academic partners. EIP works collaboratively across different programs and disease areas at CDC to deliver critical data that the program is well suited to obtain (2).
Dr. Fridkin is a senior advisor for Antibiotic Resistance in Healthcare, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC. His work involves implementing and expanding surveillance and public health research of antimicrobial drug–resistant infections associated with health care delivery.


  1. Institute of Medicine (US) Committee on Emerging Microbial Threats to Health. In: Lederberg J, Shope RE, Oaks SC, editors. Emerging infections: microbial threats to health in the United States. Washington (DC): National Academies Press (US); 1992.
  2. Pinner RWLynfield RHadler JLSchaffner WFarley MMFrank MECultivation of an adaptive domestic network for surveillance and evaluation of emerging infections. Emerg Infect Dis201521:14991509DOI
  3. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013 [cited 2015 Mar 3].http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf
  4. McCormick AWWhitney CGFarley MMLynfield RHarrison LHBennett NMGeographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med2003;9:42430DOIPubMed
  5. Kyaw MHLynfield RSchaffner WCraig ASHadler JReingold AEffect of introduction of the pneumococcal conjugate vaccine on drug-resistantStreptococcus pneumoniae. N Engl J Med2006;354:145563DOIPubMed
  6. Whitney CGFarley MMHadler JHarrison LHBennett NMLynfield RDecline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med2000;343:191724DOIPubMed
  7. Woodbury RLKlammer KAXiong YBailiff TGlennen ABartkus JMPlasmid-borne erm(T) from invasive, macrolide-resistant Streptococcus pyogenes strains. Antimicrob Agents Chemother2008;52:11403DOIPubMed
  8. Castor MLWhitney CGComo-Sabetti KFacklam RRFerrieri PBartkus JMAntibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol. 2008;2008:727505.
  9. Wu HMHarcourt BHHatcher CPWei SCNovak RTWang XEmergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med. 2009;360:886-92DOIPubMed
  10. Suggested citation for this article: Magill SS, Dumyati G, Ray SM, Fridkin SK. Evaluating the epidemiology and improving surveillance of healthcare-associated infections. Emerg Infect Dis. 2015;15371542DOI
  11. Cleveland AAFarley MMHarrison LHStein BHollick RLockhart SRChanges in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clin Infect Dis2012;55:135261DOIPubMed
  12. Lockhart SRIqbal NCleveland AAFarley MMHarrison LHBolden CBSpecies identification and antifungal susceptibility testing of Candidabloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol2012;50:343542.DOIPubMed
  13. Ahlquist AMHarrison LHFarley MMSchaffner WBeldavs ZIqbal NThe emergence of multidrug resistant Candida species: results from a population-based laboratory surveillance in the United States, 2008–2012. In: Abstracts of the 18th Congress of the International Society for Human and Animal Mycology; Berlin, Germany; 2012 Jun 11–15. Mycoses. 2012;55(Suppl 4):252. Abstract P500.
  14. Pham CDIqbal NBolden CBKuykendall RJHarrison LHFarley MMRole of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother2014;58:46906DOIPubMed
  15. Chea NBulens SNKongphet-Tran TLynfield RShaw KMVagnone PSImproved phenotype-based definition for identifying carbapenemase producers among carbapenem-resistant Enterobacteriaceae. Emerg Infect Dis. 2015;21:16116DOI
  16. Centers for Disease Control and PreventionFour pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus—Minnesota and North Dakota, 1997–1999. MMWR Morb Mortal Wkly Rep1999;48:70710 .PubMed
  17. Fridkin SKHageman JCMorrison MSanza LTComo-Sabetti KJernigan JA, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352:1436–44.
  18. Klevens RMMorrison MANadle JPetit SGershman KRay SInvasive methicillin-resistant Staphylococcus aureus infections in the United States.JAMA2007;298:176371DOIPubMed
  19. Dantes RMu YBelflower RAragon DDumyati GHarrison LHNational burden of invasive methicillin-resistant Staphylococcus aureus infections, United States. JAMA Intern Med2013;173:19708 .PubMed
  20. Centers for Disease Control and Prevention. National Antimicrobial Resistance Monitoring System for enteric bacteria (NARMS): human isolates final report, 2011. Atlanta: The Centers; 2013.
  21. Scallan EHoekstra RMAngulo FJTauxe RVWiddowson MARoy SL, et al. Foodborne illness acquired in the United States—major pathogens. Emerg Infect Dis. 2011;17:7–15.
  22. Kassenborg HDSmith KEVugia DJRabatsky-Ehr TBates MRCarter MAFluoroquinolone-resistant Campylobacter infections: eating poultry outside of the home and foreign travel are risk factors. Clin Infect Dis2004;38(Suppl 3):S27984DOIPubMed
  23. Nelson JMSmith KEVugia DJRabatsky-Ehr TSegler SDKassenborg HDProlonged diarrhea due to ciprofloxacin-resistant Campylobacterinfection. J Infect Dis2004;190:11507DOIPubMed
  24. Executive O-CA-RB. The White House. September 18, 2014 [cited 2014 Oct 28]. http://www.whitehouse.gov/the-press-office/2014/09/18/executive-order-combating-antibiotic-resistant-bacteria
Suggested citation for this article: Fridkin SK, Cleveland AA, See I, Lynfield R. Emerging Infections Program as surveillance for antimicrobial drug resistance. Emerg Infect Dis. 2015 Sep [date cited]. http://dx.doi.org/10.3201/eid2109.150512
DOI: 10.3201/eid2109.150512

No hay comentarios:

Publicar un comentario